secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001104659-26-015887
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe
--------------------------------------------------------------------------------

- Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.
- Adjusted net loss $13.5M ($0.22/share) vs adjusted net loss $21.6M ($0.89/share) a year ago.
- Revenue negatively impacted by returns reserve for short-dated product from UK distributor; unit sales more than doubled QoQ.
- Cash and equivalents $8.7M as of Dec 31, 2025 (excluding $2.4M ATM proceeds post-quarter).
- Submitted Type A meeting request to FDA to discuss ONS-5010 CRL for wet AMD; additional EU launches planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/0001104659-26-015887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-015887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer